Aspirin for Postpartum Patients With Preeclampsia

• Status: Recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MemorialCare Health System
• Collaborator: University of California, Irvine
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.

• Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic.

Exclusion Criteria:

• Patient age <18 years old

• Non-English or Non-Spanish speaking

• Chronic hypertension diagnosed before 20 weeks' gestation

• Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction)

• Aspirin prescribed postpartum for any other medical condition

• Bleeding disorder

• Breastfeeding an infant with thrombocytopenia